The publication aims to determine whether hydrochlorothiazide (HCTZ) is associated with an increased risk of skin cancer compared with angiotensin-converting enzyme inhibitors (ACEIs) and calcium channel blockers (CCBs).
Citation
Laurent Azoulay, Audray St-Jean, Matthew Dahl, Jacqueline Quail, Wusiman Aibibula, James M. Brophy, An-Wen Chan, Lauren Bresee, Greg Carney, Sherif Eltonsy, Hala Tamim, J. Michael Paterson, Robert W. Platt, Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: A multi-site population-based cohort study, Journal of the American Academy of Dermatology, 2023, ISSN 0190-9622, https://doi.org/10.1016/j.jaad.2023.04.035.
(https://www.sciencedirect.com/science/article/pii/S0190962223007351)